IRIS Accounts Production v24.3.0.553 08572161 director 1.5.23 30.4.24 30.4.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh085721612023-04-30085721612024-04-30085721612023-05-012024-04-30085721612022-04-30085721612022-05-012023-04-30085721612023-04-3008572161ns15:EnglandWales2023-05-012024-04-3008572161ns14:PoundSterling2023-05-012024-04-3008572161ns10:Director12023-05-012024-04-3008572161ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3008572161ns10:SmallEntities2023-05-012024-04-3008572161ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3008572161ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3008572161ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3008572161ns10:FullAccounts2023-05-012024-04-3008572161ns10:RegisteredOffice2023-05-012024-04-3008572161ns5:CurrentFinancialInstruments2024-04-3008572161ns5:CurrentFinancialInstruments2023-04-3008572161ns5:Non-currentFinancialInstruments2024-04-3008572161ns5:Non-currentFinancialInstruments2023-04-3008572161ns5:ShareCapital2024-04-3008572161ns5:ShareCapital2023-04-3008572161ns5:CapitalRedemptionReserve2024-04-3008572161ns5:CapitalRedemptionReserve2023-04-3008572161ns5:RetainedEarningsAccumulatedLosses2024-04-3008572161ns5:RetainedEarningsAccumulatedLosses2023-04-3008572161ns5:PlantMachinery2023-04-3008572161ns5:PlantMachinery2023-05-012024-04-3008572161ns5:PlantMachinery2024-04-3008572161ns5:PlantMachinery2023-04-3008572161ns5:CostValuation2023-04-3008572161ns5:WithinOneYearns5:CurrentFinancialInstruments2024-04-3008572161ns5:WithinOneYearns5:CurrentFinancialInstruments2023-04-30
REGISTERED NUMBER: 08572161 (England and Wales)















Unaudited Financial Statements For The Year Ended 30 April 2024

for

Ashburton Prescribing Consultants
Limited

Ashburton Prescribing Consultants
Limited (Registered number: 08572161)






Contents of the Financial Statements
For The Year Ended 30 April 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Ashburton Prescribing Consultants
Limited

Company Information
For The Year Ended 30 April 2024







DIRECTOR: Mrs L Garforth





REGISTERED OFFICE: Clock Tower Park Offices
Long Moor Lane
Liverpool
L10 1LD





REGISTERED NUMBER: 08572161 (England and Wales)





ACCOUNTANTS: Fact3
3 Hardman Square
Spinningfields
Manchester
M3 3EB

Ashburton Prescribing Consultants
Limited (Registered number: 08572161)

Balance Sheet
30 April 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 68,942 87,013
Investments 5 100 100
69,042 87,113

CURRENT ASSETS
Debtors 6 158,748 140,780
Cash at bank 252,900 132,730
411,648 273,510
CREDITORS
Amounts falling due within one year 7 113,060 72,285
NET CURRENT ASSETS 298,588 201,225
TOTAL ASSETS LESS CURRENT
LIABILITIES

367,630

288,338

CREDITORS
Amounts falling due after more than one
year

8

(10,309

)

(28,039

)

PROVISIONS FOR LIABILITIES (17,235 ) (21,753 )
NET ASSETS 340,086 238,546

CAPITAL AND RESERVES
Called up share capital 50 50
Capital redemption reserve 50 50
Retained earnings 339,986 238,446
340,086 238,546

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ashburton Prescribing Consultants
Limited (Registered number: 08572161)

Balance Sheet - continued
30 April 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 29 January 2025 and were signed by:





Mrs L Garforth - Director


Ashburton Prescribing Consultants
Limited (Registered number: 08572161)

Notes to the Financial Statements
For The Year Ended 30 April 2024

1. STATUTORY INFORMATION

Ashburton Prescribing Consultants Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation on tangible fixed assets is charged to the profit and loss so as to write off their value, over their estimated useful lives, using the following methods:

Computer equipment3 years straight line
Motor vehicle25% reducing balance

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Ashburton Prescribing Consultants
Limited (Registered number: 08572161)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 33 (2023 - 30 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 May 2023 113,879
Additions 6,974
At 30 April 2024 120,853
DEPRECIATION
At 1 May 2023 26,866
Charge for year 25,045
At 30 April 2024 51,911
NET BOOK VALUE
At 30 April 2024 68,942
At 30 April 2023 87,013

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 May 2023
and 30 April 2024 100
NET BOOK VALUE
At 30 April 2024 100
At 30 April 2023 100

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 41,392 61,703
Other debtors 117,356 79,077
158,748 140,780

Ashburton Prescribing Consultants
Limited (Registered number: 08572161)

Notes to the Financial Statements - continued
For The Year Ended 30 April 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 18,024 10,309
Taxation and social security 87,832 38,851
Other creditors 7,204 23,125
113,060 72,285

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Bank loans 10,309 28,039

9. RELATED PARTY DISCLOSURES

During the year, the balance due from General Practice Tech Solutions Limited as at 30 April 2024 was £108,115 (2023: £73,746).

All transactions occurred on an arm's length basis.